Abstract | OBJECTIVES: STUDY DESIGN:
Indomethacin therapy was started after confirming ductus arteriosus within 24 hours after birth in extremely low birth weight infants. After one cycle of therapy, infants with closed ductus were classified as responders, and those with patent ductus were classified as nonresponders. Multiple logistic regression analysis was used to determine important perinatal factors associated with persistent ductus arteriosus. Immunohistochemistry with cyclooxygenase antibodies and radioimmunoassay by 6-keto prostaglandin F(1α) kit were used to determine the relationship between intrauterine inflammation and ductal patency. RESULTS: CONCLUSIONS:
|
Authors | Eun Sun Kim, Ee-Kyung Kim, Chang Won Choi, Han-Suk Kim, Beyong Il Kim, Jung-Hwan Choi, Joong Shin Park, Kyung Chul Moon |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 157
Issue 5
Pg. 745-50.e1
(Nov 2010)
ISSN: 1097-6833 [Electronic] United States |
PMID | 20598319
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 Mosby, Inc. All rights reserved. |
Chemical References |
- Cyclooxygenase Inhibitors
- Indomethacin
|
Topics |
- Cyclooxygenase Inhibitors
(therapeutic use)
- Ductus Arteriosus, Patent
(drug therapy, epidemiology, etiology)
- Female
- Fetal Diseases
- Humans
- Indomethacin
(therapeutic use)
- Infant, Extremely Low Birth Weight
- Infant, Newborn
- Inflammation
(complications)
- Male
- Pilot Projects
- Risk Factors
- Treatment Failure
|